Nextcure and legochem biosciences enter into collaboration and co-development agreement to develop antibody drug conjugates

Beltsville, md. and daejeon, south korea, nov. 15, 2022 (globe newswire) -- nextcure, inc. (nasdaq: nxtc) and legochem biosciences, inc. (lcb, kosdaq: 141080) today announced a collaboration and co-development agreement focused on generating a b7-h4 antibody drug conjugate (adc) and options for two additional targets. the b7-h4 adc will utilize nextcure's b7-h4 antibody and lcb's conjualltm adc technology.
NXTC Ratings Summary
NXTC Quant Ranking